Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

× No keyword cloud information.

136 in total

1. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine.

Authors: R Ueno; S Kuno
Journal: Lancet Date: 1987-06-13 Impact factor: 79.321

2. HTLV-III gag protein is processed in yeast cells by the virus pol-protease.

Authors: R A Kramer; M D Schaber; A M Skalka; K Ganguly; F Wong-Staal; E P Reddy
Journal: Science Date: 1986-03-28 Impact factor: 47.728

3. Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro.

Authors: M A Liu; T Liu
Journal: J Clin Invest Date: 1988-12 Impact factor: 14.808

4. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

Authors: T J McQuade; A G Tomasselli; L Liu; V Karacostas; B Moss; T K Sawyer; R L Heinrikson; W G Tarpley
Journal: Science Date: 1990-01-26 Impact factor: 47.728

5. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors: E S Daar; X L Li; T Moudgil; D D Ho
Journal: Proc Natl Acad Sci U S A Date: 1990-09 Impact factor: 11.205

6. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.

Authors: V A Johnson; M A Barlow; D P Merrill; T C Chou; M S Hirsch
Journal: J Infect Dis Date: 1990-06 Impact factor: 5.226

7. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

Authors: J O Kahn; J D Allan; T L Hodges; L D Kaplan; C J Arri; H F Fitch; A E Izu; J Mordenti; J E Sherwin; J E Groopman
Journal: Ann Intern Med Date: 1990-02-15 Impact factor: 25.391

8. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.

Authors: D Meruelo; G Lavie; D Lavie
Journal: Proc Natl Acad Sci U S A Date: 1988-07 Impact factor: 11.205

4. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.

Authors: S D Malley; J M Grange; F Hamedi-Sangsari; J R Vila
Journal: Proc Natl Acad Sci U S A Date: 1994-11-08 Impact factor: 11.205

4 in total

Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

1. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine.

2. HTLV-III gag protein is processed in yeast cells by the virus pol-protease.

3. Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro.

4. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

5. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

6. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.

7. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

8. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.

9. A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

10. Ribavirin antagonizes the effect of azidothymidine on HIV replication.

1. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.

Review 2. Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

3. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

4. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.